Welcome to our dedicated page for Autonomix Medical news (Ticker: AMIX), a resource for investors and traders seeking the latest updates and insights on Autonomix Medical stock.
Autonomix Medical, Inc. (NASDAQ: AMIX) is a development-stage medical device company focused on precision nerve-targeted treatments for diseases involving the nervous system. News about Autonomix often centers on clinical data from its proof-of-concept studies, intellectual property milestones, and updates on its catheter-based nerve-sensing and ablation platform.
Recent announcements have highlighted subgroup analyses from the company’s PoC 1 study in pancreatic cancer pain, presented at major scientific meetings such as the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. These updates describe rapid and durable pain relief, reductions in opioid use, and quality-of-life improvements in patients with severe pancreatic cancer-related pain, including those with advanced and metastatic disease. Autonomix has also reported on its follow-on PoC 2 phase, which evaluates additional visceral cancers that signal pain through the celiac plexus and earlier-stage pancreatic cancers.
Another key theme in AMIX news is intellectual property. The company has announced U.S. and European patents titled “Controlled and Precise Treatment of Cardiac Tissues,” covering systems and methods that sense autonomic or cardiac signals, map neural targets, and deliver feedback-guided neuromodulation, denervation, and ablation. These patents support Autonomix’s stated strategy to build a global IP portfolio in nerve sensing and modulation with potential applications across cardiology, hypertension, interventional pain management, pulmonary and gastrointestinal disorders, and other high-burden diseases.
Investors following AMIX news can also expect updates on capital markets activity, including private placements, purchase agreements with institutional investors, and at-the-market sales agreements disclosed in SEC filings. For a consolidated view of Autonomix-related headlines, clinical presentations, patent issuances, and financing developments, this news feed provides an organized way to track how the company’s nerve-sensing and ablation platform is progressing through clinical and corporate milestones.
Autonomix Medical (NASDAQ: AMIX) announced that its technology and early proof-of-concept study results will be showcased at EuroPCR, a leading interventional cardiovascular medicine conference in Paris, France from May 20-23, 2025.
The presentation, titled 'Catheter-Based Transvascular RF Neural Ablation For Severe Pancreatic Cancer Pain Elpis Study', will be featured during PCR Innovators Day. The company's Chief Medical Officer, Dr. Robert S. Schwartz, will be the presenting author of the poster, highlighting Autonomix's developments in precision nerve-targeted treatments.
Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in nervous system disease diagnosis and treatment technologies, has announced an inducement stock option grant. The grant, approved by the Company's Compensation Committee on April 17, 2025, allows a new non-executive employee to purchase 5,000 shares of common stock.
The option's exercise price matches Autonomix's closing price on the Nasdaq Capital Market on April 17, 2025. The grant features a ten-year term and vests in four equal annual installments, contingent upon the employee's continued employment with the company through the vesting dates. This grant was made under Nasdaq Rule 5635(c)(4) as part of the employee's compensation package.
Autonomix Medical (NASDAQ: AMIX) has been granted European Patent No. 3,226,792 for its catheter-based technology in neuromodulation. The patent covers methods and systems for nerve monitoring and surgical procedures related to regulating prostate and tumor growth.
The technology's applications include sensing, ablating, and verifying neurological traffic to the prostate and lower urinary tract (LUT) organs, with potential to treat conditions like chronic prostatitis, hypogonadism, nocturia, and erectile dysfunction. The company's patent portfolio now includes over 80 issued patents and 40 pending applications.
While primarily focused on developing treatments for pancreatic cancer pain by targeting the celiac plexus, Autonomix plans to submit an IDE and begin U.S. clinical trials in 2025 to commercialize their Sensing and RF Ablation System.
Autonomix Medical (NASDAQ: AMIX) has announced the engagement of leading medical experts to guide its U.S. clinical and regulatory pathway for pancreatic cancer pain treatment. The advisory team includes former Society of Interventional Radiology Past Presidents Dr. Michael Brunner and Dr. Katharine Krol, along with Dr. Patricio Polanco and Dr. Nikola Cesarovic.
The company is preparing for FDA De Novo submission in 2026, with plans to initiate U.S. clinical studies in 2025. This strategic move aims to ensure their pre-clinical and clinical studies align with FDA requirements for their first-in-class technology in nervous system disease diagnosis and treatment.
Autonomix Medical (NASDAQ: AMIX) announced that its abstract on nerve-targeted treatment technology and early proof-of-concept study results has been accepted for poster presentation at the 2025 European Conference on Interventional Oncology (ECIO). The presentation, titled 'Catheter-Based Transvascular RF Neural Ablation for Severe Pancreatic Cancer Pain: First Results from The Elpis Study,' will be presented at the conference scheduled for April 13-16, 2025, in Rotterdam, Netherlands. The study's authors include Dr. Robert S. Schwartz, Chief Medical Officer of Autonomix Medical, and Dr. Askar Uktamovich Sabirov from AKFA Medline Hospital.
Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in nervous system disease diagnostics and treatment technologies, has announced an inducement stock option grant. The Compensation Committee approved on March 17, 2025, options to purchase 7,500 shares of common stock for a new non-executive employee.
The stock options, granted under Nasdaq Rule 5635(c)(4), have a ten-year term and will vest in four equal annual installments. The exercise price matches the closing price of Autonomix's common stock on the Nasdaq Capital Market as of March 17, 2025. The grant serves as part of the employee's compensation package and was provided as an inducement for their employment.
Autonomix Medical (NASDAQ: AMIX) has been granted U.S. patent 12,217,863 by the USPTO for its medical devices with circuitry for capturing and processing physiological signals. The patent protects the company's proprietary technology for real-time physiological monitoring across various applications including heart mapping, arterial mapping, and nervous system monitoring.
The company's innovative platform features a catheter-based microchip sensing array antenna that can detect neural signals with up to 3,000 times greater sensitivity than current technologies. Combined with proprietary RF ablation technology, it enables precise targeting and elimination of overactive nerves.
Autonomix plans to submit an IDE and begin U.S. clinical trials in 2025 to commercialize their Sensing and RF Ablation System for treating pancreatic cancer pain. The company's patent portfolio now includes over 80 issued patents and 40 pending applications.
Autonomix Medical (NASDAQ: AMIX) has achieved a significant milestone by completing the integration of the Apex 6 Radiofrequency Generator into its transvascular treatment platform, now branded as the Autonomix Sensing and RF Ablation System. This advancement keeps the company on schedule for its Investigational Device Exemption (IDE) submission and potential U.S. clinical trials initiation in 2025.
The integration follows the July 2024 licensing agreement with RF Innovations for the FDA-cleared Apex 6 Generator technology. The company aims to develop a treatment for pancreatic cancer pain, with the system showing promising early clinical results. Autonomix is working with RF Innovations' manufacturing partner to facilitate equipment development, targeting FDA De Novo clearance for commercialization in the U.S. market.
Autonomix Medical (NASDAQ: AMIX) announced the acceptance of their abstract for poster presentation at the 2025 Society of Interventional Radiology (SIR) Annual Scientific Meeting in Nashville, Tennessee, from March 29-April 2, 2025.
The presentation, titled 'Pain Mitigation in Pancreatic Adenocarcinoma: An Interim Analysis of Neurolysis via Transvascular RF Energy-Based Ablation', will be delivered by Dr. Bela Kis, Chief of Interventional Radiology at Moffitt Cancer Center, on Monday, March 31, at 12:10 PM CT.
The SIR conference, representing over 8,000 practicing interventional radiology professionals, focuses on advancing image-guided therapies and improving patient care through emerging methodologies and cutting-edge technologies.
Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in nervous system diagnosis and treatment technologies, has announced its participation in the LSI USA '25 Emerging Medtech Summit.
CEO Brad Hauser will deliver a presentation on March 18, 2025, at 7:35 AM PT. The company's management team will also be available for one-on-one meetings with qualified registered investors during the conference.